If the American public could shed girth as quickly as many medical journals have in recent years, we’d all be a lot healthier.
If the American public could shed girth as quickly as many medical journals have in recent years, we’d all be a lot healthier.
Collectively, medical journals dropped over 4,200 pages in 2013, as reported by MM&M last month, a direct result of fewer ad buys in the category. Professional marketers have steadily shifted resources into digital channels and other outside-the-book physician engagement activities.
But marketers should think twice about cutting off print journal plays, at least for some physician audiences, according to Jaime Hodges, EVP, healthcare, at Phoenix Marketing International. The company has developed an assessment tool that attempts to quantify the “stopping power” of a journal ad, among other things, that can influence a physician’s behavior.
To establish a set of benchmarks for effective journal advertising, Phoenix randomly selected 50 drug ads from last year’s medical journals, and asked physicians to review them according to a set criteria. “Our methodology reconstructs a mock-journal environment to try to get as close to a real-life situation as possible,” says Hodges. Phoenix is partnered with the market research firm Medefield for physician panels, and Hodges says hundreds of physicians gave input during the ad review benchmarking process.
In addition to stopping power and recall, physicians were asked to rate ads based on whether the ad reminded them of something they already knew, gave them new information, and what actions they might take as a result of seeing the ad. Actions like “prescribing the drug, prescribing it more than they already do, seeking out more information, requesting samples, and testing their rep about the product,” says Hodges. “We’re finding that a third of the physicians will report a high likelihood – a six or a seven on a seven-point scale – to take at least one of those actions.” About a quarter of physicians “strongly agree” that a journal ad can be a good reminder, even when it’s not anchored to a new product or new indication, she says.
Other findings include:
Asked about a correlation between high-performing ads and prescription uptick or other proven ROI measures, Hodges says the company hasn’t completed the validation process yet, but hopes to tie its ad review product – Journal AdPi – to drug sales in the future. “The real barrier is access to prescribing data…it’s difficult to get unless we get it from our clients.”
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.